ScreenerHero

HRTXHeron Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · herontx.com
0.3182USD+1.05%Mkt Cap: 60.41M $P/E: —

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap60.41M $
Enterprise Value165.40M $
Revenue (TTM)151.18M $
Gross Profit113.56M $
Net Income (TTM)-20.20M $
Revenue/Share0.8180 USD
Last Price0.3182 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4277461020
Valuation
P/E (Trailing)—
P/E (Forward)-2.81
PEG—
EV/EBITDA-18.94
EV/Revenue1.09
P/S0.39
P/B9.97
EPS (TTM)-0.19
EPS (Forward)-0.11
52W Range
0.30301% of range1.580
52W High1.580 USD
52W Low0.3030 USD
Profitability
Gross Margin73.31%
Oper. Margin-5.43%
EBITDA Margin-5.78%
Profit Margin-13.04%
ROE-140.90%
ROA-7.89%
Growth
Revenue Growth1.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.59M $
CapEx (TTM)317.00K $
FCF Margin-5.85%
FCF Yield-14.63%
Net Debt105.69M $
Net Debt/EBITDA-12.11
Balance Sheet
Debt/Equity9.81
Current Ratio2.49
Quick Ratio1.44
Book Value/Sh0.0310 USD
Cash/Share0.2250 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 13, 2014
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+2099.9%
Target Range5.000 USD – 9.000 USD
$5.000+2099.9% to mean$9.000
# Analysts3
Ownership
Shares Out.189.85M
Float146.52M
Insiders0.98%
Institutions71.05%
Short Interest
Short Ratio17.4d
Short % Float29.09%
Short % Out.22.82%
Shares Short43.24M
Short (prev mo.)40.50M
Technical
SMA 500.4252 (-25.2%)
SMA 2000.9291 (-65.7%)
Beta1.67
S&P 52W Chg18.16%
Avg Vol (30d)2.83M
Avg Vol (10d)4.43M
Technical Indicators
RSI (14)26.5
MACD-0.0447
MACD Signal-0.0314
MACD Hist.-0.0133
BB Upper0.5893 USD
BB Middle0.4244 USD
BB Lower0.2596 USD
BB Width77.68%
ATR (14)0.0391 USD
Vol Ratio (20d)1.09x